Please login to the form below

Not currently logged in
Email:
Password:

HTA

This page shows the latest HTA news and features for those working in and with pharma, biotech and healthcare.

ICER says Alnylam’s Onpattro should cost 90%-95% less

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even after discounts the medication exceeds the cost-effectiveness threshold. A US health technology assessment (HTA) group has concluded that Alnylam’s just-approved Onpattro for hereditary transthyretin (hATTR) amyloidosis is

Latest news

  • UK, Germany back routine use of J&J’s Tremfya UK, Germany back routine use of J&J’s Tremfya

    The swift decision by two of Europe’s key HTA bodies reflects the positive results demonstrated in clinical studies of guselkumab for the treatment of moderate to severe plaque psoriasis,” said

  • 2018 by Darwin 2018 by Darwin

    As failed launches slow uptake and HTA rejections show us, a business model that has most of the costs of innovation but delivers few of its benefits is usually selected against

  • Transforming access in rare diseases Transforming access in rare diseases

    Project HERCULES is a unique initiative set to radically improve the way evidence is generated for HTA submissions. ... history of the disease and developing a new quality of life metric, which is essential in cost-utility based HTA processes.

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    It aims “aims to radically simplify the way evidence is generated for submissions to HTA bodies, such as the National Institute for Health and Care Excellence (NICE)”, according to Duchenne UK, ... HTA agencies can struggle with decisions in the

  • EMA forges closer ties with HTA umbrella group EMA forges closer ties with HTA umbrella group

    EMA and HTAs such as the UK’s National Institute for Health and Care Excellence (NICE) in parallel rather than sequentially. ... introduced tool to try to standardise the assessment process for new medicinal products and avoid duplicating work by

More from news
Approximately 30 fully matching, plus 133 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 14 fully matching, plus 53 partially matching documents found.

Latest appointments

  • Open Access Consulting appoints new director Open Access Consulting appoints new director

    value dossiers, payer-focused objection handlers, stand-alone payer value propositions and local HTA submissions.

  • Claes Buxfeldt joins NDA Claes Buxfeldt joins NDA

    He becomes its new HTA director. AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board. ... Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA

  • Professor Carole Longson moves from NICE to the ABPI Professor Carole Longson moves from NICE to the ABPI

    She most recently spent the 18 years at the National Institute for Health and Care Excellence ( NICE), where she has led the HTA organisation’s technology appraisal programme.

  • VCLS appoints Carole Jones to senior market access role VCLS appoints Carole Jones to senior market access role

    her focus on expanding the company’s market access capabilities, spanning payer strategy, health economics and outcomes research (HEOR), health technology assessment (HTA) and communications support.

  • EFPIA's Richard Torbett to move to the ABPI EFPIA's Richard Torbett to move to the ABPI

    At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics